Estimation of magnesium in patients with functional hypoparathyroidism

Subramanian Kannan; Shriraam Mahadevan; P Velayutham; R Bharath; V Kumaravel; J Muthukumaran; A Premkumar

doi:10.4103/2230-8210.141365

Estimation of magnesium in patients with functional hypoparathyroidism

Indian J Endocrinol Metab. 2014 Nov;18(6):821-5. doi: 10.4103/2230-8210.141365.

Authors

Subramanian Kannan¹, Shriraam Mahadevan², P Velayutham³, R Bharath⁴, V Kumaravel⁵, J Muthukumaran⁶, A Premkumar⁷

Affiliations

¹ Department of Endocrinology, Diabetology and Bariatric Medicine, Narayana Health City, Bengaluru, Karnataka, India.
² Department of Endocrinology, Sri Ramachandra Medical College, Porur, Tamil Nadu, India.
³ Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India.
⁴ Department of Endocrinology, Chettinad Medical College, Madurai, Tamil Nadu, India.
⁵ Alpha Hospital and Research Centre, Madurai, Tamil Nadu, India.
⁶ Arka Center for Hormonal Health, Adyar, Chennai, Tamil Nadu, India.
⁷ SKS Hospital, Salem, Tamil Nadu, India.

Abstract

Context: It is evident that about 30-50% of patients with Vitamin D deficiency (VDD) do not manifest develop secondary hyperparathyroidism (SHPT). A number of theories have been proposed to explain this lack of SHPT, including hypomagnesemia.

Settings and design: Retrospective review of laboratory database.

Materials and methods: We evaluated the differences in serum magnesium (Mg) levels among those with VDD with or without SHPT. A retrospective review of 6255 laboratory data of bone mineral profiles performed in the period of 2007-2013. After excluding patients with hypercalcemia, renal dysfunction/unknown kidney function and primary hypothyroidism, the remaining 1323 patient data were analyzed. SHPT was defined as serum parathyroid hormone >65 in those with VDD.

Statistical analysis used: ANOVA and Wilcoxon tests as appropriate to compare means. Multivariate logistic regression to analyze relation between variables and outcome of SHPT.

Results: We noted that 55% patients (n = 727) had VDD, and among those who had VDD, 23% (n = 170) were hypocalcemic (corrected serum calcium <8.5). Patients with VDD who did not exhibit SHPT were 56% (n = 407). The mean (±standard deviation) serum Mg levels in the entire cohort (n = 1323) was 1.94 ± 0.26 mg/dl and 1.95 ± 0.26 mg/dl in VDD cohort and 2 ± 0.31 mg/dl in the VDD-hypocalcemic cohort. There was no statistical difference in the Mg levels among those with SHPT compared to those without SHPT (P = 0.14). Serum calcium and phosphorus were lower in those with SHPT (P = 0.06 and P < 0.001, respectively). In multivariate logistic regression, serum calcium (P = 0.043), phosphorus (P < 0.001) and severe VDD (P < 0.001) independently correlated with occurrence of SHPT in VDD.

Conclusions: Serum Mg levels did not explain the functional hypoparathyroidism seen in about half of the patients with VDD. A low normal serum calcium and phosphorus levels are more likely to be associated with VDD patients who develop SHPT.

Keywords: Calcium; Vitamin D deficiency; hyperparathyroidism; magnesium; phosphorus.